(1)
BASEL (dpa-AFX) - Today s Daily Dose brings you news about temporary suspension of bluebird bio s gene therapy trials in sickle cell disease, Sesen Bio s regulatory catalyst for this year, partial hold on Cortexyme s open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer s disease, and expanded FDA approval of Novartis Entresto.
Read on.
1. Sickle Cell Disease Trial Blues For bluebird bio
Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as the company s LentiGlobin gene therapy trials for sickle cell disease were temporarily suspended after two cases of cancer were reported in study participants.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Abbott Laboratories (NYSE:ABT) - The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Abeona Therapeutics Inc (NASDAQ:ABEO) - The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
(3)
LONDON (dpa-AFX) - Today s Daily Dose brings you news about Applied Genetic s Achromatopsia trial results; the deadlock in AstraZeneca vaccine supply in EU; partnership of Lilly, Vir Biotech and GlaxoSmithKline in fighting COVID-19; and ZymeWork s progress with ZW49 study.
Read on.
1. Applied Genetic Throws Light on Achromatopsia Trials
Applied Genetic Technologies Corp. s (AGTC) phase I/II clinical trials evaluating AAV gene therapy product candidates in patients with achromatopsia caused by CNGB3 or CNGA3 mutations, dubbed ACHMB3 and ACHMA3 trials, have provided for the first time quantitative evidence of improvements in visual sensitivity.
Achromatopsia (ACHM) is an inherited condition caused by mutations in one of several genes, with the two most common being mutations in either the CNGB3 or CNGA3 genes.